Acute Effects of Non-Oil-Seed Pulses on Parameters of Cardiometabolic Health: A Systematic Review of Human Intervention Studies.

Nutr RevSep 1, 2026
Clinical ResearchCardiologyEndocrinologyGastroenterology

Tim B Schiemann, Christina Diekmann, Sarah Egert

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the acute effects of non-oil-seed pulses on cardiometabolic health parameters in humans. It found that 28 of 40 studies reported lower glucose responses and 16 of 24 studies reported lower insulin responses compared to control foods. The review highlights the potential of non-oil-seed pulses as low-glycemic foods.

Key findings

  • 28 of 40 studies reported lower glucose responses after consuming non-oil-seed pulses compared to control foods.
  • 16 of 24 studies showed lower insulin responses following pulse consumption versus control groups.
  • 3 of 5 studies found a significant reduction in hunger after meals enriched with pulses.

Why it matters

Understanding the impact of non-oil-seed pulses on glycemic control and satiety can inform dietary recommendations for managing cardiometabolic health, particularly in populations at risk for diabetes and obesity.

Source

PubMed · PMID 41317035

Published in Nutr Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.